stockrowBeam Therapeutics Inc.
BEAM Healthcare Biotechnology
Beam Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $139.7 million, up 120.0% from fiscal 2024.
- Revenue
- −96.8%
- EPS
- −16.7%
- Free cash flow
- −29.5%
Quarter to September 2026, against a year earlier
Follow BEAM
Alert me
Beam Therapeutics Inc. (BEAM) Shares outstanding
Beam Therapeutics Inc.'s shares outstanding at the end of fiscal 2025 was $98.9M, up 20.2% from $82.3M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $104.7M. Over the past ten years it has ranged from $2.9M (fiscal 2018) to $98.9M (fiscal 2025) — the current reading is the highest in ten years. Beam Therapeutics Inc. ranks 137th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $98.9M | 20.16% |
| FY2024 | $82.3M | 6.69% |
| FY2023 | $77.2M | 10.19% |
| FY2022 | $70.0M | 9.01% |
| FY2021 | $64.2M | 37.43% |
| FY2020 | $46.7M | 621.24% |
| FY2019 | $6.5M | 123.90% |
| FY2018 | $2.9M | (94.18%) |
| FY2017 | $49.7M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $104.7M | 0.36% |
| Jun 2026 | $104.3M | 1.03% |
| Mar 2026 | $103.3M | 4.40% |
| Dec 2025 | $98.9M | (3.57%) |
| 27 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| RCUS Arcus Biosciences, Inc. compare | $127.4M |
| NAMS NewAmsterdam Pharma Company N.V. compare | $124.1M |
| ZLAB Zai Lab Limited Unsponsored ADR compare | $111.7M |
| VRDN Viridian Therapeutics, Inc. compare | $107.9M |
| BEAM Beam Therapeutics Inc. | $104.7M |
| IDYA IDEAYA Biosciences, Inc. compare | $102.9M |
| XNCR Xencor, Inc. compare | $75.9M |
| MBX MBX Biosciences, Inc. compare | $47.7M |
| TLX Telix Pharmaceuticals Limited compare | — |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on BEAM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement